Acquired Autoimmune Hemolytic Anemia Industry Valued at $2.88 Billion by 2029 With CAGR of 7.4% | Size and Share Insights
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
#What Is the Forecast for the Acquired Autoimmune Hemolytic Anemia Market from 2024 to 2025?#_x000D_
The market size for acquired autoimmune hemolytic anemia has seen a significant increase in recent times. An expected growth from $2.01 billion in 2024 to $2.16 billion in 2025, with a Compound Annual Growth Rate (CAGR) of 7.5%, is forecasted. Factors contributing to the historical period growth include a surge in diagnostic rates, an increased number of secondary AIHA, expanding hospital hematology units, support from government and regulatory bodies, addition to escalated investments in the hematology sector._x000D_
_x000D_
#What Is the Projected Market Size of the Acquired Autoimmune Hemolytic Anemia Market?#_x000D_
Expectations are high that the market for acquired autoimmune hemolytic anemia will experience robust growth in the coming years. With a projected compound annual growth rate (CAGR) of 7.4%, it is forecast to reach $2.88 billion by 2029. This upward trend can be credited to factors such as the increasing prevalence of autoimmune disorders, a better comprehension of the complement system’s role, strengthening partnerships between biopharma companies and academic institutions, the growing use of tailor-made medicine, and an increasing aged population. Key trends to watch during this forecast period include the implementation of target-specific biologic therapies, advances in complement pathway inhibitors, the utilization of AI and data analytics in managing diseases, AI-driven clinical trial designs, and advancements in orphan drug development._x000D_
_x000D_
#Download The Free Sample Report Here:#_x000D_
https://www.thebusinessresearchcompany.com/sample.aspx?id=24132&type=smp_x000D_
_x000D_
#Who are the Major Competitors in the Acquired Autoimmune Hemolytic Anemia Market Outlook?#_x000D_
Major companies operating in the acquired autoimmune hemolytic anemia market are Johnson & Johnson, F. Hoffmann-La Roche Ltd., AbbVie Inc., Sanofi SA, Novartis AG, Amgen Inc., Incyte Corporation, Alexion Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Annexon Inc., Rigel Pharmaceuticals Inc., Nanjing IASO Biotherapeutics Co. Ltd., Apellis Pharmaceuticals Inc., Momenta Pharmaceuticals Inc., Zenas BioPharma Inc., Immunovant Sciences GmbH, Alpine Immune Sciences Inc., Agios Pharmaceuticals Inc., Rakshit Drugs Private Limited, Aarti Pharmalabs Ltd._x000D_
_x000D_
#What Is Fueling Growth in the Acquired Autoimmune Hemolytic Anemia Market?#_x000D_
A surge in autoimmune disorders, conditions where the body’s immune system erroneously attacks its own healthy cells and tissues, is expected to boost the acquired autoimmune hemolytic anemia market’s expansion. This surge can largely be attributed to increases in environmental triggers and lifestyle shifts that may interfere with the regulation of the immune system. The escalating rate of autoimmune disorders leads to an increased occurrence of acquired autoimmune hemolytic anemia, as individuals with these disorders are at a higher risk of developing secondary AIHA due to immune system malfunction. In 2022, for example, according to the autoimmune registry, a US-based organization that collects and assesses data on autoimmune conditions, the percentage of patients diagnosed with multiple autoimmune conditions increased from 52% in 2021 to 55% in 2022. Thus, the increasing rate of autoimmune disorders will spur the expansion of the acquired autoimmune hemolytic anemia market._x000D_
_x000D_
#Request For A Customized Report:#_x000D_
https://www.thebusinessresearchcompany.com/sample.aspx?id=24132&type=smp_x000D_
_x000D_
#Which Acquired Autoimmune Hemolytic Anemia Market Segments Are Growing the Fastest?#_x000D_
The acquired autoimmune hemolytic anemia market covered in this report is segmented –_x000D_
_x000D_
1) By Diagnosis Method: Complete Blood Count, Peripheral Blood Smear, Direct Coombs Test, Indirect Coombs Test_x000D_
2) By Treatment Type: Corticosteroids, Immunosuppressive Agents, Intravenous Immunoglobulin, Rituximab_x000D_
3) By Severity: Mild, Moderate, Severe_x000D_
4) By End User: Hospitals, Specialty Clinics, Research Institutions_x000D_
_x000D_
Subsegment:_x000D_
1) By Complete Blood Count: Hemoglobin Level, Hematocrit (HCT), Reticulocyte Count, White Blood Cell Count, Platelet Count_x000D_
2) By Peripheral Blood Smear: Spherocytes, Polychromasia, Schistocytes, Increased Reticulocyte Count_x000D_
3) By Direct Coombs Test: Immunoglobulin G Coombs Test, Immunoglobulin M Coombs Test, Complement Coombs Test_x000D_
4) By Indirect Coombs Test: Screening For Alloantibodies, Detection Of Sensitizing Antibodies, Crossmatch Testing_x000D_
_x000D_
#Which Industry Trends Are Shaping the Future of the Acquired Autoimmune Hemolytic Anemia Market?#_x000D_
Key players in the acquired autoimmune hemolytic anemia market are concentrating on developing advanced targeted therapies like humanized monoclonal antibodies. This approach aims to enhance the effectiveness of treatments, minimize adverse effects, and offer more individualized care to patients suffering from autoimmune hemolytic anemia. Humanized monoclonal antibodies are lab-created proteins that replicate human antibodies, consisting primarily of human elements but also incorporating small segments of non-human (typically mouse) antibodies. This dual nature boosts its capacity to pinpoint specific antigens while decreasing the likelihood of rejection by the immune system. For example, in February 2022, France’s healthcare corporation, Sanofi, obtained approval from the U.S. Food and Drug Administration for Enjaymo (sutimlimab-jome), the maiden and single therapy for cold agglutinin disease (CAD)—a rare form of autoimmune hemolytic anemia. Enjaymo operates by selectively undermining C1s in the classical complement pathway, shielding healthy red blood cells from immune system attacks and hence reducing the demand for red blood cell transfusions among CAD patients. Notably, Enjaymo purposely targets C1-induced hemolysis without impeding the lectin or alternative complement pathways._x000D_
_x000D_
#Access The Full Report Here:#_x000D_
_x000D_
#Which Countries Are Leading the Acquired Autoimmune Hemolytic Anemia Market?#_x000D_
North America was the largest region in the acquired autoimmune hemolytic anemia market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the acquired autoimmune hemolytic anemia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
#Purchase The Full Report Today:#_x000D_
https://www.thebusinessresearchcompany.com/customise?id=24132&type=smp_x000D_
_x000D_
#This Report Delivers Insight On: #_x000D_
1. How big is the acquired autoimmune hemolytic anemia market, and how is it changing globally?_x000D_
2. Who are the major companies in the acquired autoimmune hemolytic anemia market, and how are they performing?_x000D_
3. What are the key opportunities and risks in the acquired autoimmune hemolytic anemia market right now?_x000D_
4. Which products or customer segments are growing the most in the acquired autoimmune hemolytic anemia market?_x000D_
5. What factors are helping or slowing down the growth of the acquired autoimmune hemolytic anemia market?_x000D_
_x000D_
#About The Business Research Company:#_x000D_
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_
_x000D_
#Get in touch with us:#_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas +1 310-496-7795_x000D_
Europe +44 7882 955267_x000D_
Asia & Others +44 7882 955267 & +91 8897263534_x000D_
Email us at info@tbrc.info_x000D_
_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
